Literature DB >> 11897543

Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers.

Antoine U Viola1, Gabrielle Brandenberger, Michel Toussaint, Philippe Bouhours, Jean Paul Macher, Remy Luthringer.   

Abstract

OBJECTIVES: To determine the effect on sleep electroencephalographic (EEG) activity of ritanserin, a serotonin-2 (5-HT2) receptor antagonist in young poor sleepers.
METHODS: Eight male subjects underwent two randomized night studies after receiving either a placebo or 5 mg ritanserin administered in the morning. The overnight variations in the delta (0.5-4.0 Hz) and sigma (12.25-15.0 Hz) frequency bands were characterized using a peak analysis which provided a quantitative evaluation of the time-courses in EEG activity.
RESULTS: In subjects under ritanserin, slow wave sleep duration and the number of non-rapid eye movement (NREM)-REM sleep cycles were significantly enhanced (P<0.01). The number of peaks in delta activity occurring in the normal 80-120 min range was significantly (P<0.05) increased. Using a delta peak analysis, 4 periods containing or not a significant peak were identified in each subject. A significant increase in delta activity was observed in the areas under the averaged curves during the second and the third periods (P<0.05), while sigma activity decreased under ritanserin during the first, second and third periods (P<0.05).
CONCLUSIONS: These results demonstrate that ritanserin increases delta activity, possibly by opposing the inhibitory control of 5-HT2 receptor family. It restores sleep ultradian rhythmicity and improves sleep quality in young poor sleepers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897543     DOI: 10.1016/s1388-2457(02)00014-7

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  10 in total

1.  Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

Authors:  Sandra Giménez; Susana Clos; Sergio Romero; Eva Grasa; Adelaida Morte; Manuel J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

2.  Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.

Authors:  Heike E Kuenzel; Axel Steiger; Katja Held; Irina A Antonijevic; Ralf-Michael Frieboes; Harald Murck
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 3.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

4.  Drug-related Sleep Stage Changes: Functional Significance and Clinical Relevance.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Sleep Med Clin       Date:  2010-12-01

5.  Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.

Authors:  Sonia Ancoli-Israel; Kimberly E Vanover; David M Weiner; Robert E Davis; Daniel P van Kammen
Journal:  Sleep Med       Date:  2011-01-21       Impact factor: 3.492

6.  Effect of Modified Yukmijihwang-Tang on Sleep Quality in the Rat.

Authors:  SunYoung Lee; Hun-Soo Lee; Minsook Ye; Min-A Kim; Hwajung Kang; Sung Ja Rhie; Mi Young Lee; In Chul Jung; In-Cheol Kang; Insop Shim
Journal:  Clocks Sleep       Date:  2022-05-27

7.  Sleep quality varies as a function of 5-HTTLPR genotype and stress.

Authors:  Beverly H Brummett; Andrew D Krystal; Allison Ashley-Koch; Cynthia M Kuhn; Stephan Züchner; Ilene C Siegler; John C Barefoot; Edna L Ballard; Lisa P Gwyther; Redford B Williams
Journal:  Psychosom Med       Date:  2007-08-31       Impact factor: 4.312

8.  Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.

Authors:  Luc Staner
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

9.  Role of 5-HT2A receptor antagonists in the treatment of insomnia.

Authors:  Kimberly E Vanover; Robert E Davis
Journal:  Nat Sci Sleep       Date:  2010-07-28

10.  Chronic upper airway obstruction induces abnormal sleep/wake dynamics in juvenile rats.

Authors:  Gideon Gradwohl; Nilly Berdugo-Boura; Yael Segev; Ariel Tarasiuk
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.